Association of a Haplotype in the Promoter Region of the Interferon Regulatory Factor 5 Gene With Rheumatoid Arthritis

Snaevar Sigurdsson,1 Leonid Padyukov,2 Fina A. S. Kurreeman,3 Ulrika Liljedahl,1 Ann-Christin Wiman,1 Lars Alfredsson,4 René Toes,3 Johan Rönnelid,1 Lars Klareskog,2 Tom W. J. Huizinga,3 Gunnar Alm,5 Ann-Christine Syvänen,1 and Lars Rönnblom1

Objective. To determine whether genetic variants of the interferon regulatory factor 5 (IRF-5) and Tyk-2 genes are associated with rheumatoid arthritis (RA).

Methods. Five single-nucleotide polymorphisms (SNPs) in IRF5 and 3 SNPs in Tyk2 were analyzed in a Swedish cohort of 1,530 patients with RA and 881 controls. A replication study was performed in a Dutch cohort of 387 patients with RA and 181 controls. All patient sera were tested for the presence of autoantibodies against cyclic citrullinated peptides (anti-CCP).

Results. Four of the 5 SNPs located in the 5′ region of IRF5 were associated with RA, while no association was observed with the Tyk2 SNPs. The minor alleles of 3 of the IRF5 SNPs, which were in linkage disequilibrium and formed a relatively common haplotype with a frequency of ~0.33, appeared to confer protection against RA. Although these disease associations were seen in the entire patient group, they were mainly found in RA patients who were negative for anti-CCP. A suggestive association of IRF5 SNPs with anti-CCP–negative RA was also observed in the Dutch cohort.

Conclusion. Given the fact that anti-CCP–negative RA differs from anti-CCP–positive RA with respect to genetic and environmental risk factor profiles, our results indicate that genetic variants of IRF5 contribute to a unique disease etiology and pathogenesis in anti-CCP–negative RA.

The type I interferons (IFNs) comprise a large family of cytokines that are typically produced during viral infections, mainly by plasmacytoid dendritic cells (1). In addition to direct antiviral effects, type I IFNs have many important immunomodulatory functions (1). For instance, they cause maturation of dendritic cells, promote T cell activation, and stimulate B cell development and production of antibodies. Data from previous studies indicate that the type I IFN system plays a pivotal role when self tolerance is broken and autoimmune reactions develop (2). Accordingly, the type I IFN system is activated in many autoimmune diseases, including systemic lupus erythematosus (SLE) (2), pri-
mary Sjögren’s syndrome (3), psoriasis (4), polymyositis (5), and type 1 diabetes mellitus (6).

In a previous report we described a strong association between SLE and 2 key genes from the type I IFN signaling system, namely the Tyk-2 and interferon regulatory factor (IRF-5) genes (7). The association of the single-nucleotide polymorphisms (SNPs) in the IRF-5 gene with SLE has recently been convincingly replicated in 4 independent case–control studies (8). A causative role of type I IFN in the initiation and maintenance of autoimmunity is suggested by the finding that up to 19% of IFNα-treated patients with a malignant disease ultimately developed an autoimmune disorder (2). Development of rheumatoid arthritis (RA) is a common autoimmune disease characterized by chronic arthritis with progressive joint destruction, and if left untreated RA can lead to severe disability. RA affects women 2–3 times more frequently than it affects men, and both genetic and environmental components are involved in the etiopathogenesis of the disease (10). A majority of RA patients are positive for autoantibodies against the Fc portion of the IgG molecule (rheumatoid factor [RF]). The presence of RF in patients correlates with a severe form of RA (11), but RF can occasionally be detected in normal healthy individuals and in patients with conditions other than RA (12).

It has been shown that RA patients also produce antibodies against cyclic citrullinated peptides (anti-CCP), and that anti-CCP antibodies are rarely detectable in healthy individuals (13). They are thus a more specific disease marker for RA than is RF. Anti-CCP antibodies can be detected years before the appearance of any clinical RA symptoms (14), and they are prognostic indicators of a greater degree of inflammation and more destructive disease (15). Recent data on gene–environment interactions also show that the major environmental risk factor, smoking, is associated with anti-CCP–positive RA, but not with anti-CCP–negative RA (10,16). Furthermore, anti-CCP antibodies display a strong association with specific alleles at the HLA-DRB1 gene (10), which are collectively known as shared epitope alleles. In contrast, the HLA-DR3 allele is associated with anti-CCP–negative RA, which suggests that the syndrome called RA may consist of at least 2 distinct diseases (anti-CCP positive and anti-CCP negative), each with different risk factors and pathogenetic pathways (17). Genetic variants of several non–major histocompatibility complex (MHC) genes have also shown an association with RA (18), and among them the most convincing evidence for association has been observed for variants of the PTPN22 (MIM no. 600716) (19), PADI4 (MIM no. 605347) (20), and CTLA4 (MIM no. 123890) (21,22) genes. The PTPN22 allele, which has shown the most consistent association with RA in previously published studies, is associated with anti-CCP–positive RA (18). So far, no genetic risk factor outside the HLA locus has been identified for anti-CCP–negative disease.

The role of the type I IFN system in RA has not been extensively investigated, but expression of IFNα (23) and the type I IFN–inducible protein myxovirus resistance protein A (24) has been detected in RA synovial tissue, along with increased levels of IFNα in synovial fluid (25). Furthermore, plasmacytoid dendritic cells are recruited to inflamed synovium (26), perhaps due to increased levels of production of chemoattractants for these cells in the synovial fluid (24). Moreover, the cytokines interleukin-6 (IL-6), IL-10, IL-12, and tumor necrosis factor α (TNFα), which are connected to the type I IFN pathway, have all been suggested to be involved in the disease process in RA (27).

The JAK Tyk-2 is crucial for signaling via the type I IFN receptor. Tyk-2 also interacts with the receptors for several other cytokines, such as IL-6, IL-10, and IL-12. A possible role of Tyk-2 in RA is more directly indicated by the finding that Tyk-2–deficient mice are resistant to experimental arthritis (28). IRF-5 is a transcription factor that is activated by Toll-like receptor 7 (TLR-7), TLR-8, and TLR-9, which are involved in induction of IFNα genes in human cells (29,30). IRF-5 is constitutively expressed in cells of the immune system, including plasmacytoid dendritic cells (31), and its expression is regulated by type I IFN (32).

Given the potential role of the type I IFN system in RA, we hypothesized that genetic variants of Tyk2 and IRF5 could be associated with RA, by analogy with our previous findings in SLE (7). To test this hypothesis, we genotyped 5 SNPs in the IRF-5 gene and 3 SNPs in the Tyk-2 gene in a large cohort of RA patients and controls from Sweden. We found that 4 of the 5 IRF5 SNPs and a commonly observed haplotype formed by the rare alleles of these SNPs were strongly associated with RA, and that the evidence of association was mainly found in anti-CCP–negative RA. We replicated the association between IRF5 and anti-CCP–negative RA in an unrelated cohort of Dutch patients.
PATIENTS AND METHODS

Samples. The Swedish RA patients and controls were from the Epidemiological Investigation of Rheumatoid Arthritis (EIRA), a population-based case–control study of incident cases of RA. The EIRA included subjects ages 18–70 years who were living in the central and southern parts of Sweden during 1996–2003. Briefly, all potential cases were examined and diagnosed by a rheumatologist at a study unit. All rheumatology units linked to the public health care system, as well as almost all of the few existing privately run rheumatology units, in the relevant geographic area participated in the study. In total there were 19 reporting clinics, 15 of which were Early Arthritis Clinics. Initially, some centers reported cases that did not satisfy the criteria for RA, in order to enable investigations of undifferentiated arthritis, but these subjects were eventually excluded from the study.

For each potential case, a control subject was randomly selected from the study base, with consideration of age, sex, and area of residence. Controls were selected using the Swedish national population register, which is continuously updated. If a proposed control declined to participate, was not traceable, or was reported as having RA, a new control was selected using the same criteria. Controls selected to match cases who were eventually excluded because they did not fulfill study criteria remained in the study.

In the present study we used part of the EIRA cohort consisting of 1,530 newly diagnosed patients who fulfilled the 1987 American College of Rheumatology (formerly, the American Rheumatism Association) criteria for RA (33), and 881 controls who answered a questionnaire and provided a blood sample. Among the cases, the mean duration between estimated disease onset and study entry was 10 months. Of all participants in the EIRA study, 97% were Caucasian. Seventeen controls who were found to be positive for anti-CCP antibodies and 3 controls with unknown anti-CCP status were excluded from the analysis.

The replication cohort consisted of RA patients and controls from the Leiden Early Arthritis Clinic, as previously described in detail (34). Briefly, in 1993, an Early Arthritis Clinic was established at the Department of Rheumatology of the Leiden University Medical Center. General practitioners in an area with ~300,000 inhabitants referred patients directly to the clinic when arthritis was suspected. All patients were evaluated at the Early Arthritis Clinic within 2 weeks of referral. Patients were included in the study only if the duration of symptoms was <2 years, and the mean duration between estimated disease onset and study entry was 7 months. Diagnoses were made according to international classification criteria, as previously described (35).

Patients from the Early Arthritis Clinic who were diagnosed as having definite RA, and from whom DNA was available, were included in the present study (n = 387). Other anti-CCP–negative and RF-negative patients from the Early Arthritis Clinic with diagnoses such as gout, pseudogout, viral or bacterial reactive arthritis, posttraumatic osteoarthritis, Lyme arthritis, or paraneoplastic arthritis made up the control group (n = 181). Patients with undifferentiated arthritis, psoriatic arthritis, or SLE were excluded from the control group. All subjects in the case and control groups were Caucasian.

All subjects in both cohorts gave informed consent, and the local ethics committee approved the study. DNA was isolated from EDTA-treated blood by a standard desalting method.

Autoantibody analysis. Patient sera obtained from the EIRA cohort at the time of diagnosis were examined for RF by nephelometry and for anti-CCP antibodies by enzyme-linked immunosorbent assay (ELISA) (second-generation test; Euro-Diagnostica, Arnhem, The Netherlands). Antinuclear antibodies (ANAs) were measured in 194 anti-CCP–positive and 191 anti-CCP–negative patients with RA using indirect immunofluorescence on HEp-2 cells (Bio-Rad, Stockholm, Sweden) in a 1:200 screening dilution with a secondary antibody directed against the γ-chain of IgG (Dako, Glostrup, Denmark). All sera were interpreted blindly in parallel, by the same investigator (JR). Using this procedure, ANAs were detected in sera from 5% (5%) of 100 healthy controls. In the Early Arthritis Clinic study, serum anti-CCP antibodies were assessed with a commercial ELISA (Immunoscan RA [Mark 2]; Euro-Diagnostica). Anti-CCP antibodies were measured in serum collected within 4 months after the first visit (in 94% of the patients) or, when serum was not available within this period, in the first stored serum sample available thereafter.

Genotyping. In the Swedish EIRA cohort we genotyped 4 SNPs in the promoter and first intron of the IRF-5 gene (rs729302, rs2004640, rs752637, and no. rs3807306) and 2 SNPs in protein-coding exons of the Tyk-2 gene (rs12720356 and rs2304256) for which we had observed strong or suggestive signals for joint linkage and association with SLE in a previous study (7). We also included in the analysis an additional SNP in the promoter region of IRF5 (rs3757385) and a Tyk2 SNP (rs91755) located in intron 9 between the SNPs rs2304256 in exon 8 and rs12720356 in exon 15 of Tyk2.

Six of the SNPs were genotyped by multiplex minisequencing (fluorescence single-base extension) with the SNPStream Genotyping System (Beckman Coulter, Fullerton, CA) (36), and 2 SNPs (rs752637 and rs2304256) were genotyped using a homogeneous single-base extension assay with fluorescence polarization detection (FP-TDI; PerkinElmer, Emeryville, CA) (37). Four SNPs in the IRF-5 gene (rs729302, rs3757385, rs2004640, and rs3807306) were genotyped for replication in samples from the Dutch Early Arthritis Clinic study, using the SNPStream System as described above. The SNPs were genotyped at the SNP technology platform in Uppsala (www.genotyping.se). The sequences of the polymerase chain reaction and minisequencing primers used in the genotyping assays are available from the corresponding author upon request.

The mean SNP genotype call rate in the EIRA samples was 94% (range 92–97%), and the accuracy estimated from 3,700 genotype comparisons between repeated assays (18% of the genotypes) was 99.9%. In the Early Arthritis Clinic study samples, the mean call rate was 98% (range 95–99%), and the accuracy based on repeated determination of 10% of the genotypes was 100%. All SNPs exhibited Hardy-Weinberg equilibrium (P > 0.01 by Fisher’s exact test) in both sample sets.

Statistical analysis. Unadjusted 2-tailed P values calculated by Fisher’s exact test were used to compare the SNP allele frequencies in the RA patient groups versus the controls.
‡ Odds ratios (ORs) were calculated using the formula
\[
\text{OR} = \frac{\text{odds in cases}}{\text{odds in controls}}
\]

Single-nucleotide polymorphisms (SNPs) rs729302, rs3757385, rs2004640, rs752637, and rs3807306 are in the interferon regulatory factor 5 (IRF-5) gene; SNPs rs12720356, rs91755, and rs2304256 are in the Tyk-2 gene. Rheumatoid factor (RF) status could not be determined in 85 patients, and anti–cyclic citrullinated peptide antibody (anti-CCP) status could not be determined in 21 patients.

Prior to performing a pooled analysis of the 2 independent cohorts, lack of heterogeneity in the populations was confirmed using the Breslow-Day test of homogeneity (39). The EasyMA 2001 software package (39) was used for the pooled analysis, using the Mantel-Haenszel test for calculating ORs. The EIRA and Early Arthritis Clinic cohorts demonstrated \( P \) values for homogeneity \( > 0.01 \) for all 4 loci tested. The frequencies of ANAs in the EIRA patient and control sera were compared using a chi-square test.

### RESULTS

Association analysis using the genotype data for the individual SNPs from all Swedish patients and controls revealed that 4 of the 5 analyzed SNPs in the IRF-5 gene were associated with RA (\( P < 0.05 \)), with SNP rs3807306 exhibiting the strongest association (\( P = 0.00063 \)) (Table 1). In contrast, we did not find evidence of an association between RA and any of the SNPs in the Tyk-2 gene (\( P > 0.05 \)). We also analyzed the genotype data from RA patients stratified into subgroups according to presence or absence of RF and stratified into subgroups according to presence or absence of anti-CCP autoantibodies, compared with the data from all controls. In the RF-positive patients, only SNP rs3807306 showed evidence of association with RA, whereas in the RF-negative patients 4 of the IRF5 SNPs showed evidence of association.

No significant differences in the minor allele frequencies of any of the SNPs were observed when RF-positive and RF-negative patients were compared (data not shown). There was a slight difference between anti-CCP–positive and anti-CCP–negative patients in

### Table 1. Analysis of the association of individual SNPs in the IRF-5 and Tyk-2 genes with RA in all Swedish patients and controls, and in Swedish patients after stratification based on the presence or absence of RF or anti-CCP antibodies

<table>
<thead>
<tr>
<th>RefSNP no., major/minor SNP allele</th>
<th>rs729302, A/C</th>
<th>rs3757385, C/A</th>
<th>rs2004640, T/G</th>
<th>rs752637, G/A</th>
<th>rs3807306, A/C</th>
<th>rs12720356, T/G</th>
<th>rs91755, G/T</th>
<th>rs2304256, C/A</th>
</tr>
</thead>
<tbody>
<tr>
<td>Minor allele frequency</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Controls (n = 861)</td>
<td>0.31</td>
<td>0.36</td>
<td>0.48</td>
<td>0.37</td>
<td>0.50</td>
<td>0.09</td>
<td>0.48</td>
<td>0.30</td>
</tr>
<tr>
<td>All patients (n = 1,530)</td>
<td>0.32</td>
<td>0.31</td>
<td>0.44</td>
<td>0.33</td>
<td>0.45</td>
<td>0.09</td>
<td>0.47</td>
<td>0.29</td>
</tr>
<tr>
<td>RF+ patients (n = 956)</td>
<td>0.33</td>
<td>0.33</td>
<td>0.45</td>
<td>0.34</td>
<td>0.46</td>
<td>0.08</td>
<td>0.47</td>
<td>0.28</td>
</tr>
<tr>
<td>RF− patients (n = 489)</td>
<td>0.31</td>
<td>0.30</td>
<td>0.42</td>
<td>0.32</td>
<td>0.44</td>
<td>0.11</td>
<td>0.46</td>
<td>0.29</td>
</tr>
<tr>
<td>Anti-CCP+ patients (n = 919)</td>
<td>0.33</td>
<td>0.32</td>
<td>0.45</td>
<td>0.34</td>
<td>0.47</td>
<td>0.08</td>
<td>0.47</td>
<td>0.29</td>
</tr>
<tr>
<td>Anti-CCP− patients (n = 590)</td>
<td>0.31</td>
<td>0.30</td>
<td>0.43</td>
<td>0.32</td>
<td>0.43</td>
<td>0.11</td>
<td>0.47</td>
<td>0.28</td>
</tr>
</tbody>
</table>

\( P \) versus controls†

| All patients (n = 1,530)          | NS            | 0.0012         | 0.0067         | 0.007         | 0.00063        | NS             | NS             | NS             |
| RF+ patients (n = 956)            | NS            | NS             | NS             | NS           | 0.008          | NS             | NS             | NS             |
| RF− patients (n = 489)            | NS            | 0.0032         | 0.0035         | 0.012         | 0.0023         | NS             | NS             | NS             |
| Anti-CCP+ patients (n = 919)      | NS            | 0.013          | NS             | 0.043         | 0.035          | NS             | NS             | NS             |
| Anti-CCP− patients (n = 590)      | NS            | 0.0022         | 0.0036         | 0.01          | 0.000091       | NS             | NS             | NS             |

OR (95% CI)‡

| Anti-CCP+ patients (n = 919)      | 1.09 (0.94–1.26) | 0.83 (0.72–1.01) | 0.89 (0.77–1.01) | 0.86 (0.75–0.99) | 0.86 (0.75–0.98) | ND             | ND             | ND             |
| Anti-CCP− patients (n = 590)      | 1.02 (0.86–1.19) | 0.77 (0.65–0.91) | 0.80 (0.68–0.92) | 0.81 (0.69–0.95) | 0.73 (0.62–0.85) | ND             | ND             | ND             |

\* Single-nucleotide polymorphisms (SNPs) rs729302, rs3757385, rs2004640, rs752637, and rs3807306 are in the interferon regulatory factor 5 (IRF-5) gene; SNPs rs12720356, rs91755, and rs2304256 are in the Tyk-2 gene. Rheumatoid factor (RF) status could not be determined in 85 patients, and anti–cyclic citrullinated peptide antibody (anti-CCP) status could not be determined in 21 patients. 95% CI = 95% confidence interval; NS = not significant; ND = not determined.

† Unadjusted 2-tailed \( P \) values comparing each patient group with controls were calculated using Fisher’s exact test. The empirical \( P \) values for association with anti-CCP–negative rheumatoid arthritis (RA) (100,000 permutations obtained using Haploview software, version 3.2) were \( P = 0.024 \) for SNP rs3757385, \( P = 0.042 \) for SNP rs2004640, and \( P = 0.0008 \) for SNP rs3807306. The \( P \) value for SNP rs752637 was not significant.

‡ Odds ratios (ORs) were calculated using the formula \( \text{OR} = \frac{\text{odds in cases}}{\text{odds in controls}} \), where \( i \) and \( j \) are allele counts in patients with RA and in controls, respectively.
the minor allele frequency of SNP rs3807306 ($P = 0.036$). The most striking result of this analysis was the strong evidence of association observed for the 4 IRF5 SNPs in the group of anti-CCP–negative patients. Despite the fact that this subgroup of patients ($n = 590$) constituted only approximately one-third of all patients with RA, evidence of association for SNP rs3807306 was stronger in this subgroup ($P = 0.000091$) than it was in the original analysis of all patients and controls (Table 1). This association was also evident in a codominant model ($P = 0.0003$; data not shown).

When the RA patients were stratified into subgroups according to a combination of presence or absence of RF and anti-CCP antibodies, most of the evidence of association was found in the group of patients who were negative for both anti-CCP and RF. In this group, which included only approximately one-fifth of all patients ($n = 366$), the observed $P$ values were 0.0035, 0.0082, and 0.0026 for SNPs rs3757385, rs2004640, and rs3807306, respectively. Stratification of the patients according to anti-CCP and RF status did not reveal any evidence of association of the 3 Tyk2 SNPs with RA.

We did not detect any significant sex-specific differences in Tyk2 or IRF5 SNP allele frequencies in the RA patient or control groups (data not shown). The minor allele frequencies of the IRF5 SNPs were, however, lower in the male patients who were negative for both anti-CCP and RF ($n = 100$) than in the male controls ($n = 250$), and a significantly lower minor allele frequency was noted for SNP no. rs2004640 in this subgroup compared with that in male controls (0.35 versus 0.49; $P = 0.000911$). Table 1 shows the ORs for the 5 IRF5 SNPs in the subgroups of anti-CCP–positive and anti-CCP–negative patients. The frequency of the minor, variant alleles of the associated SNPs was lower in the RA patient groups than in the controls, reducing the risk of RA to 0.7–0.8 compared with carriers of the major alleles. Thus, these alleles appeared to be protective against RA.

Figure 1 shows the positions of the SNPs in the IRF-5 gene and the pairwise linkage disequilibrium values between the SNPs rs3757385, rs2004640, rs752637, and rs3807306 in the control samples from Sweden. Table 2 shows the frequencies of the haplotypes formed by these 4 IRF-5 SNPs in anti-CCP–negative RA patients, anti-CCP–positive RA patients, and controls. The 3 most common haplotypes, H1–H3, accounted for almost 90% of the genetic variation conferred by these SNPs in the sample set. The most common haplotype, H1, which is formed by the more frequent alleles of the SNPs, appeared to be a risk haplotype for anti-CCP–negative RA, with an OR of 1.23 (95% confidence interval [95% CI] 1.06–1.43). The frequency of the second most common haplotype, H2, which is formed by the minor alleles of the 4 SNPs, displayed the strongest evidence of association with RA ($P = 0.000080$), and was associated with protection against anti-CCP–negative RA, with an OR of 0.71 (95% CI 0.60–0.84). For anti-CCP–positive RA, the OR for haplotype H2 was 0.85 (95% CI 0.74–0.98).

To attempt to replicate the association between the IRF-5 gene and anti-CCP–negative RA, we genotyped 4 of the IRF-5 SNPs in an unrelated cohort of Dutch RA patients (Table 3). The SNP allele frequencies were similar in the Swedish and Dutch patient and control groups, and evidence of association was observed for SNP rs2004640 in the group of anti-CCP–negative patients ($P = 0.024$). Also, $P$ values for SNPs rs729302 and rs3757385 ($P = 0.072$ and $P = 0.091$, respectively) suggested an association in the anti-CCP–negative patients, but, possibly due to the small number of individuals in this group, the evidence of this associ-
did not reach the formal threshold for statistical significance.

In a combined analysis of all 741 anti-CCP–negative patients in the cohorts from both populations, which were genetically homogeneous (\textit{P}/H_{1}0.01 by heterogeneity test), strong evidence of association of SNPs rs2004640 and rs3807306 with anti-CCP–negative RA was exhibited (\textit{P}/H_{1}0.001). Table 3 shows the ORs for the 4 IRF-5 SNPs analyzed in the Dutch cohort and the combined ORs for all anti-CCP–negative patients in both cohorts. In the Dutch samples the haplotypes formed by SNPs rs3757385, rs2004640, and rs3807306 occurred with similar frequencies as in the Swedish samples (data not shown).

The strongest evidence of association with RA in the Swedish cohort was observed for the \textit{IRF5} SNP rs3807306. This SNP is in relatively high linkage disequilibrium with SNP rs2004640 (Figure 1), which is associated with SLE, and the minor alleles of these 2 SNPs are on the same protective haplotype in both SLE and RA. To test for phenotypic similarities between SLE and anti-CCP–negative RA, we measured ANAs, which are characteristic of SLE, in a subgroup of 385 RA patients and 100 age- and sex-matched controls from the EIRA cohort. We noted an increased frequency of ANAs in the RA patient samples (78 of 385) compared with the healthy control sera (5 of 100) (\textit{P}/H_{1}0.0005), but there was no difference between anti-CCP–positive and anti-

<table>
<thead>
<tr>
<th>Minor allele frequency</th>
<th>rs729302, A/C</th>
<th>rs3757385, C/A</th>
<th>rs2004640, T/G</th>
<th>rs3807306, A/C</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dutch controls (n = 181)</td>
<td>0.35</td>
<td>0.40</td>
<td>0.51</td>
<td>0.49</td>
</tr>
<tr>
<td>All Dutch patients (n = 387)</td>
<td>0.30</td>
<td>0.36</td>
<td>0.45</td>
<td>0.48</td>
</tr>
<tr>
<td>Anti-CCP– Dutch patients (n = 151)</td>
<td>0.28</td>
<td>0.33</td>
<td>0.42</td>
<td>0.46</td>
</tr>
<tr>
<td>\textit{P} versus controls†</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All Dutch patients (n = 387)</td>
<td>0.17</td>
<td>0.27</td>
<td>0.08</td>
<td>0.41</td>
</tr>
<tr>
<td>Anti-CCP– Dutch patients (n = 151)</td>
<td>0.072</td>
<td>0.091</td>
<td>0.024</td>
<td>0.279</td>
</tr>
<tr>
<td>Anti-CCP– Dutch and Swedish patients (n = 741)‡</td>
<td>0.23</td>
<td>0.0019</td>
<td>0.00089</td>
<td>0.00029</td>
</tr>
<tr>
<td>OR (95% CI)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All Dutch patients (n = 387)</td>
<td>0.83 (0.62–1.09)</td>
<td>0.80 (0.66–1.13)</td>
<td>0.80 (0.61–1.04)</td>
<td>0.90 (0.69–1.17)</td>
</tr>
<tr>
<td>Anti-CCP– Dutch patients (n = 151)</td>
<td>0.73 (0.51–1.04)</td>
<td>0.76 (0.54–1.06)</td>
<td>0.70 (0.50–0.96)</td>
<td>0.84 (0.61–1.16)</td>
</tr>
<tr>
<td>Anti-CCP– Dutch and Swedish patients (n = 741)§</td>
<td>0.98 (0.85–1.13)</td>
<td>0.81 (0.70–0.92)</td>
<td>0.75 (0.65–0.86)</td>
<td>0.78 (0.68–0.89)</td>
</tr>
</tbody>
</table>

* SNPs rs729302, rs3757385, rs2004640, and rs3807306 are in the \textit{IRF5} gene. See Table 1 for definitions.
† Unadjusted 2-tailed \textit{P} values comparing patient groups with controls were calculated using Fisher’s exact test.
‡ Fisher’s procedure was used for combining the \textit{P} values for anti-CCP–negative RA in the Dutch and Swedish data sets. \textit{P} values for the Swedish anti-CCP–negative patients are shown in Table 1.
§ EasyMA 2001 software was used for the pooled analysis, using the Mantel-Haenszel test to calculate ORs.
DISCUSSION

The data presented here provide strong evidence of an association between IRF-5 gene variants and RA, and show that the IFN pathway can be involved in this disease. Interestingly, in both the Swedish and Dutch cohorts we detected the most significant association with the IRF5 SNPs in the subgroup of anti-CCP–negative RA patients, which constituted approximately one-third of the RA patient population. Previously, no gene, with the exception of the HLA–DR3 allele (17,40), has been found to be exclusively associated with anti-CCP–negative RA. This is particularly important because the pathogenesis of anti-CCP–negative disease is poorly understood, and specific drugs for this subset of patients with RA are lacking.

Other genes that have displayed an association with RA, such as the shared epitope alleles (17) and the PTPN22 gene (18), are associated with anti-CCP–positive RA. Anti-CCP–positive and anti-CCP–negative RA patients have clinically similar phenotypes at diagnosis, but can differ with respect to the course of the disease, and anti-CCP–negative RA patients usually develop a milder form of the disease (41). The results of the present study further support the notion that genetic background is important in the differences observed between anti-CCP–positive and anti-CCP–negative RA.

The relevant SNPs are located in or close to the first intron of the IRF-5 gene. This region contains a CpG island, which is an indication of regulatory activity, and several promoters, including one with an IFN-stimulated response element site that is activated by type I IFN and one with an IRF element site that is activated by IRF-5 and IRF-1 (42). SNP rs2004640 is located in a 5′ splice donor site of an alternate exon 1, and recent data indicate that there is an allele-specific effect of this SNP on the expression pattern of different isoforms of the IRF-5 gene (8).

Because IRF-5 is an important mediator of signals from TLR-7–TLR-9 (29,43), we speculate that certain expression patterns of the IRF-5 gene can modify IRF-5–dependent induction of type I IFN, proinflammatory cytokines (e.g., IL-6, TNFα, IL-12, and IL-1β), and several chemokines (44,45). Furthermore, the level of TLR-7 expression is increased in RA synovium and can contribute to synergistic cytokine production by dendritic cells (46). These cytokines can obviously influence the development and expression of inflammatory diseases, both at the level of the underlying autoimmune process and by promoting the inflammatory process. However, IRF-5 can also increase the expression levels of several genes coding for proteins that mediate cell growth arrest and apoptosis (45). Consequently, polymorphisms within the IRF-5 gene may affect several cellular functions of importance for RA susceptibility, besides the type I IFNs. However, understanding the possible functions of the allele variants of the IRF-5 gene on the molecular level requires further experimental studies.

The clear association of SNPs in the IRF-5 gene with anti-CCP–negative RA that we observed in the present study leads us to believe that the pathogenesis of this variant form of RA may be similar to the proposed pathogenesis of SLE that we described earlier (2). The findings of the present study suggest that future investigations of anti-CCP–negative RA should focus on the role of IFNα, as well as on the role of environmental agents, such as infections, that may trigger IFNα-related pathways. In a more general sense, the present clear demonstration of an association of an important non-MHC gene with anti-CCP–negative RA, but not with anti-CCP–positive RA, provides further evidence that appropriate phenotyping of RA patients and inclusion of sufficiently large study cohorts are fundamental prerequisites for future genetic and functional studies.

In summary, we now have evidence that in RA one set of genes and environmental triggers related to T cell activation and immune reactions against specific types of autoantigens (citrullinated proteins) is related to one subset of the disease, the anti-CCP–positive variant, whereas other sets of genes appear to be related to the other major subset of the disease, the anti-CCP–negative one. Thus, anti-CCP–positive RA and anti-CCP–negative RA should be considered as phenotypically distinct subsets of RA with respect to their genetic and environmental risk factors, as well as with respect to their molecular pathogenesis. In fact, we suggest that these subsets of RA should be regarded as 2 distinct diseases and treated as such in future studies.

Addendum. After submission of this manuscript, reports of 2 studies showing no association between RA and 2 SNPs in the IRF-5 gene were published (47,48). The reasons for this seeming discrepancy could be related to the fact that the sizes of the cohorts used in the present study were larger and, perhaps more importantly, that patients in the present study were stratified according to anti-CCP antibody status.
ACKNOWLEDGMENTS

We thank all of the members of the EIRA study group who contributed to the collection of the blood samples that provided the basis for this study. The names of the EIRA group members and their affiliations can be found in reference 10.

AUTHOR CONTRIBUTIONS

Dr. Rönnblom had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study design. Sigurdsson, Padyukov, Alfredsson, Kläreskog, Alm, Syvänen, Rönnblom.

Acquisition of data. Sigurdsson, Liljedahl, Wiman, Alfredsson, Toes, Rönnelid, Huizinga, Rönnblom.


Statistical analysis. Sigurdsson, Padyukov, Kurreman, Huizinga.

Supervision of genotyping laboratory. Syvänen.

REFERENCES


